{"transactions":[{"id":723992,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:37:15.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001556064-26-000002","document":"form4-06292026_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000155606426000002/form4-06292026_080611.xml","form_type":"4"}},{"id":1113457,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:26:40.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-25-017058","document":"form4-06122025_100637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925017058/form4-06122025_100637.xml","form_type":"4"}},{"id":1122852,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-05T00:35:43.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":29747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full on the earlier of:  (i) June 3, 2026 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":29747,"derivative":{"exercise_price":10.9,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":29747},"source":{"system":"sec-edgar","filing":"0001415889-25-015700","document":"form4-06052025_120640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000141588925015700/form4-06052025_120640.xml","form_type":"4"}},{"id":1465509,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:03:53.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1121604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":1121604,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1121604},"source":{"system":"sec-edgar","filing":"0001104659-24-076895","document":"tm2418639-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465924076895/tm2418639-6_4seq1.xml","form_type":"4"}},{"id":1486721,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-06-07T20:21:31.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":7639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full on the earlier of:  (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":7639,"derivative":{"exercise_price":16.41,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":7639},"source":{"system":"sec-edgar","filing":"0001415889-24-015968","document":"form4-06072024_080627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000141588924015968/form4-06072024_080627.xml","form_type":"4"}},{"id":1488469,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T21:54:34.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":4.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-24-015826","document":"form4-06062024_090630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924015826/form4-06062024_090630.xml","form_type":"4"}},{"id":1832070,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-07-10T21:01:03.000Z","date":"2023-07-10","kind":"sale","planned":false,"acquired":false,"shares":47702,"price":0.9108,"value":43446.9816,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on July 5, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.9100 to $0.9211, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 611,224 ADSs and share options covering an aggregate of 11,093,593 ordinary shares of the Issuer. Included in the 611,224 ADSs are 200,646 ADSs held by the Garry E. Menzel Revocable Trust of 2022 (the \"Menzel Trust\") and 200,647 ADSs held by the Mary E. Henshall Revocable Trust of 2022 (the \"Henshall Trust\"). The Reporting Person is the trustee of the Menzel Trust and the Reporting Person's spouse is the trustee of the Henshall Trust and, as such, the Reporting Person may be deemed to beneficially own these securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust and the Henshall Trust."}],"balance_after":75056,"source":{"system":"sec-edgar","filing":"0001104659-23-079700","document":"tm2320966-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923079700/tm2320966-1_4seq1.xml","form_type":"4"}},{"id":1835257,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":2158776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The exercise price was converted from GBP0.09, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":2158776,"derivative":{"exercise_price":0.11,"expiration_date":"2032-12-14","underlying":"Ordinary Shares","underlying_shares":2158776},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835256,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":2715816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":2715816,"derivative":{"exercise_price":0.57,"expiration_date":"2031-12-08","underlying":"Ordinary Shares","underlying_shares":2715816},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835255,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":57846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":57846,"derivative":{"exercise_price":0.57,"expiration_date":"2031-12-08","underlying":"Ordinary Shares","underlying_shares":57846},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835254,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":3568026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price was converted from GBP0.51, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":3568026,"derivative":{"exercise_price":0.65,"expiration_date":"2028-07-25","underlying":"Ordinary Shares","underlying_shares":3568026},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835253,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":359700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price was converted from GBP0.51, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":359700,"derivative":{"exercise_price":0.65,"expiration_date":"2028-07-25","underlying":"Ordinary Shares","underlying_shares":359700},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835252,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":1251966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding and unexercised options to acquire shares of TCRR common stock (each, a \"TCRR Option\") were assumed by the Issuer and substituted for an option to purchase Ordinary Shares (each, an \"Adjusted Option\"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the Ordinary Share Exchange Ratio. The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price was converted from GBP0.07, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":1251966,"derivative":{"exercise_price":0.08,"expiration_date":"2027-12-07","underlying":"Ordinary Shares","underlying_shares":1251966},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1835251,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Ordinary Shares","published_at":"2023-07-05T21:00:22.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":736548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub was merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, outstanding restricted stock units with respect to TCRR common stock (each, a \"TCRR RSU\") were assumed by the Issuer and substituted for a restricted stock unit-style option to purchase Ordinary Shares (each, an \"Adjusted Restricted Stock Unit Equivalent\"), with an exercise price equal to GBP0.001, the nominal value of an Ordinary Share and on substantially similar terms and conditions as were applicable to such TCRR RSUs."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The number of Ordinary Shares subject to the Adjusted Restricted Stock Unit Equivalent is equal to (A) the ADS Exchange Ratio multiplied by six (such product, the \"Ordinary Share Exchange Ratio\") multiplied by (B) the total number of shares of TCRR common stock subject to such TCRR RSU. Each Adjusted Restricted Stock Unit Equivalent was granted to the Reporting Person on the date set out in Column 3."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":736548,"derivative":{"exercise_price":0.0013,"expiration_date":"2024-03-15","underlying":"Ordinary Shares","underlying_shares":736548},"source":{"system":"sec-edgar","filing":"0001104659-23-078195","document":"tm2320409-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923078195/tm2320409-8_4seq1.xml","form_type":"4"}},{"id":1839332,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-07-03T21:03:31.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":981463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":981463,"derivative":{"exercise_price":0.16,"exercise_date":"2024-07-03","expiration_date":"2033-07-03","underlying":"Ordinary Shares","underlying_shares":981463},"source":{"system":"sec-edgar","filing":"0001104659-23-077669","document":"tm2320409-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923077669/tm2320409-5_4seq1.xml","form_type":"4"}},{"id":1854286,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-15T22:25:31.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":19441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date."}],"balance_after":19441,"derivative":{"exercise_price":12.46,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":19441},"source":{"system":"sec-edgar","filing":"0001209191-23-037535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919123037535/doc4.xml","form_type":"4"}},{"id":1871675,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-06-01T20:59:07.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":209931,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share of the Issuer (each, an \"ADS\") represents six ordinary shares of the Issuer (each, an \"Ordinary Share\"), nominal value GBP 0.001 per Ordinary Share, of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub will be merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the \"ADS Exchange Ratio\"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share."},{"field":"kind","element":"transactionCoding","label":"F7","text":"Received 209,931 ADSs, representing 1,259,586 Ordinary Shares of the Issuer in exchange for 138,871 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received 209,931 ADSs, representing 1,259,586 Ordinary Shares of the Issuer in exchange for 138,871 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement."}],"balance_after":209931,"source":{"system":"sec-edgar","filing":"0001104659-23-067118","document":"tm2317417-4_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923067118/tm2317417-4_4.xml","form_type":"4"}},{"id":1871674,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-06-01T20:59:07.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":200647,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share of the Issuer (each, an \"ADS\") represents six ordinary shares of the Issuer (each, an \"Ordinary Share\"), nominal value GBP 0.001 per Ordinary Share, of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub will be merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the \"ADS Exchange Ratio\"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Received 200,647 ADSs, representing 1,203,882 Ordinary Shares in exchange for 132,730 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received 200,647 ADSs, representing 1,203,882 Ordinary Shares in exchange for 132,730 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ADSs held by the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the \"Henshall Trust\"). The Reporting Person's spouse is the trustee of the Henshall Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Henshall Trust."}],"balance_after":200647,"source":{"system":"sec-edgar","filing":"0001104659-23-067118","document":"tm2317417-4_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923067118/tm2317417-4_4.xml","form_type":"4"}},{"id":1871673,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-06-01T20:59:07.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":200646,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share of the Issuer (each, an \"ADS\") represents six ordinary shares of the Issuer (each, an \"Ordinary Share\"), nominal value GBP 0.001 per Ordinary Share, of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub will be merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the \"ADS Exchange Ratio\"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the \"Merger Agreement\"), by and among the Issuer, CM Merger Sub, Inc. (\"Merger Sub\") and TCR2 Therapeutics, Inc. (\"TCRR\"), among other things, Merger Sub will be merged with and into TCRR (the \"Merger\") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the \"ADS Exchange Ratio\"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ADSs held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the \"Menzel Trust\"). The Reporting Person is the trustee of the Menzel Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust."}],"balance_after":200646,"source":{"system":"sec-edgar","filing":"0001104659-23-067118","document":"tm2317417-4_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1556064/000110465923067118/tm2317417-4_4.xml","form_type":"4"}},{"id":1872124,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39681,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"kind","element":"transactionCoding","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":39681},"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872123,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"kind","element":"transactionCoding","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23165},"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872122,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"kind","element":"transactionCoding","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15120},"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872121,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"kind","element":"transactionCoding","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a \"Restricted Stock Unit\"), other than Restricted Stock Units that immediately vest upon a change of control of the Company, were assumed and substituted for a restricted stock unit-style option to purchase Parent Ordinary Shares or Parent ADS, with an exercise price per Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an \"Adjusted Restricted Stock Unit Equivalent\"), granted under one of Parent's incentive equity plans."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3241},"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872120,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":238008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":0.97,"underlying":"Common Stock","underlying_shares":238008},"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872119,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":305800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":5.21,"underlying":"Common Stock","underlying_shares":305800},"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872118,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":433037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":5.88,"underlying":"Common Stock","underlying_shares":433037},"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872117,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":138031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":0.74,"underlying":"Common Stock","underlying_shares":138031},"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872116,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":138871,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872115,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":132730,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Consists of 132,730 Shares held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the \"Henshall Trust\"). The Reporting Person's spouse is the trustee of the Henshall Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Henshall Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1872114,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-01T16:22:53.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":132729,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 132,729 Shares held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the \"Menzel Trust\"). The Reporting Person is the trustee of the Menzel Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-067053","document":"tm2317472-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067053/tm2317472-5_4seq1.xml","form_type":"4"}},{"id":1889103,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:08:54.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008245","document":"form4-05182023_010546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008245/form4-05182023_010546.xml","form_type":"4"}},{"id":2081789,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit (Right to Buy)","published_at":"2022-12-19T17:32:14.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":39681,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units will vest 25% on the one-year anniversary of the date of grant, with the remainder vesting in three equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units will vest 25% on the one-year anniversary of the date of grant, with the remainder vesting in three equal annual installments thereafter."}],"balance_after":39681,"derivative":{"underlying":"Common Stock","underlying_shares":39681},"source":{"system":"sec-edgar","filing":"0000899243-22-039027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322039027/doc4.xml","form_type":"4"}},{"id":2081788,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-19T17:32:14.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":238008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on the one-year anniversary of the date of grant, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":238008,"derivative":{"exercise_price":0.97,"expiration_date":"2032-12-14","underlying":"Common Stock","underlying_shares":238008},"source":{"system":"sec-edgar","filing":"0000899243-22-039027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322039027/doc4.xml","form_type":"4"}},{"id":2088066,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-13T20:19:57.000Z","date":"2022-12-13","kind":"sale","acquired":false,"shares":11000,"price":1.062,"value":11682.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."}],"balance_after":138871,"source":{"system":"sec-edgar","filing":"0000899243-22-038380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322038380/doc4.xml","form_type":"4"}},{"id":2088065,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-13T20:19:57.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":10613,"price":1.1,"value":11674.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."}],"balance_after":149871,"source":{"system":"sec-edgar","filing":"0000899243-22-038380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322038380/doc4.xml","form_type":"4"}},{"id":2088064,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-13T20:19:57.000Z","date":"2022-12-09","kind":"sale","acquired":false,"shares":10325,"price":1.131,"value":11677.575,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."}],"balance_after":160484,"source":{"system":"sec-edgar","filing":"0000899243-22-038380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322038380/doc4.xml","form_type":"4"}},{"id":2091203,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-09T16:44:15.000Z","date":"2022-12-08","kind":"sale","acquired":false,"shares":9314,"price":1.254,"value":11679.756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."}],"balance_after":170809,"source":{"system":"sec-edgar","filing":"0000899243-22-038098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322038098/doc4.xml","form_type":"4"}},{"id":2091202,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-09T16:44:15.000Z","date":"2022-12-07","kind":"sale","acquired":false,"shares":9111,"price":1.282,"value":11680.302,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."}],"balance_after":180123,"source":{"system":"sec-edgar","filing":"0000899243-22-038098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322038098/doc4.xml","form_type":"4"}},{"id":2093317,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-07T19:56:04.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":14886,"price":1.349,"value":20081.214,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.333 to $1.371. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request"}],"balance_after":189234,"source":{"system":"sec-edgar","filing":"0000899243-22-037941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322037941/doc4.xml","form_type":"4"}},{"id":2093316,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-07T19:56:04.000Z","date":"2022-12-05","kind":"sale","acquired":false,"shares":8530,"price":1.372,"value":11703.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.371 to $1.372. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":204120,"source":{"system":"sec-edgar","filing":"0000899243-22-037941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322037941/doc4.xml","form_type":"4"}},{"id":2096264,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Unit","published_at":"2022-12-05T19:49:20.000Z","date":"2022-12-01","kind":"exercise","acquired":true,"shares":21382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025."}],"balance_after":23165,"derivative":{"underlying":"Common Stock","underlying_shares":21382},"source":{"system":"sec-edgar","filing":"0001209191-22-059881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919122059881/doc4.xml","form_type":"4"}},{"id":2096263,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Unit","published_at":"2022-12-05T19:49:20.000Z","date":"2022-12-01","kind":"exercise","acquired":true,"shares":40881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024."}],"balance_after":15120,"derivative":{"underlying":"Common Stock","underlying_shares":40881},"source":{"system":"sec-edgar","filing":"0001209191-22-059881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919122059881/doc4.xml","form_type":"4"}},{"id":2096262,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Unit","published_at":"2022-12-05T19:49:20.000Z","date":"2022-12-01","kind":"exercise","acquired":true,"shares":158795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"98% of these restricted stock units vested on December 1, 2022, and the remaining 2% will vest on December 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"98% of these restricted stock units vested on December 1, 2022, and the remaining 2% will vest on December 1, 2023."}],"balance_after":3241,"derivative":{"underlying":"Common Stock","underlying_shares":158795},"source":{"system":"sec-edgar","filing":"0001209191-22-059881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919122059881/doc4.xml","form_type":"4"}},{"id":2096261,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-05T19:49:20.000Z","date":"2022-12-02","kind":"sale","acquired":false,"shares":8408,"price":1.39,"value":11687.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."}],"balance_after":212650,"source":{"system":"sec-edgar","filing":"0001209191-22-059881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919122059881/doc4.xml","form_type":"4"}},{"id":2096260,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-05T19:49:20.000Z","date":"2022-12-01","kind":"exercise","acquired":true,"shares":221058,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."}],"balance_after":221058,"source":{"system":"sec-edgar","filing":"0001209191-22-059881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919122059881/doc4.xml","form_type":"4"}},{"id":2110436,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":43726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 43,726."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"48% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"48% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025."}],"balance_after":43726,"derivative":{"underlying":"Common Stock","underlying_shares":43726},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110435,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"disposition_to_issuer","acquired":false,"shares":240488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 43,726."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"This cancelled option vested 25% on January 1, 2022 and the remaining 75% vests in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":31.83,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":240488},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110434,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":821,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 821."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"48% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"48% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025."}],"balance_after":821,"derivative":{"underlying":"Common Stock","underlying_shares":821},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110433,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"disposition_to_issuer","acquired":false,"shares":4512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 821."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"This cancelled option vested 25% on January 1, 2022 and the remaining 75% vests in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":31.83,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":4512},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110432,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":54834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 54,834."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"73% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"73% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024."}],"balance_after":54834,"derivative":{"underlying":"Common Stock","underlying_shares":54834},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110431,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"disposition_to_issuer","acquired":false,"shares":164500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 54,834."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This cancelled option vested 25% on January 1, 2021 and the remaining 75% vests in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":16.1,"expiration_date":"2029-12-18","underlying":"Common Stock","underlying_shares":164500},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110430,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":1167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,167."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"73% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"73% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024."}],"balance_after":1167,"derivative":{"underlying":"Common Stock","underlying_shares":1167},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110429,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"disposition_to_issuer","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,167."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This cancelled option vested 25% on January 1, 2021 and the remaining 75% vests in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":16.1,"expiration_date":"2029-12-18","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110428,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":159956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 159,956."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023."}],"balance_after":159956,"derivative":{"underlying":"Common Stock","underlying_shares":159956},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110427,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"disposition_to_issuer","acquired":false,"shares":479866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 159,956."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This cancelled option vested 25% on January 1, 2020 and the remaining 75% vests in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":16.11,"expiration_date":"2029-04-10","underlying":"Common Stock","underlying_shares":479866},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110426,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":2080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 2,080."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023."}],"balance_after":2080,"derivative":{"underlying":"Common Stock","underlying_shares":2080},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2110425,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T16:56:03.000Z","date":"2022-11-17","kind":"disposition_to_issuer","acquired":false,"shares":6240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 2,080."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This cancelled option vested 25% on January 1, 2020 and the remaining 75% vests in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":16.11,"expiration_date":"2029-04-10","underlying":"Common Stock","underlying_shares":6240},"source":{"system":"sec-edgar","filing":"0000899243-22-036395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322036395/doc4.xml","form_type":"4"}},{"id":2172937,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-08-26T16:30:58.000Z","date":"2022-07-05","kind":"gift","acquired":true,"shares":132730,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the \"Henshall Trust\").  The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the \"Henshall Trust\").  The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust."}],"balance_after":132730,"source":{"system":"sec-edgar","filing":"0000899243-22-029864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322029864/doc4.xml","form_type":"4"}},{"id":2172936,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-08-26T16:30:58.000Z","date":"2022-07-05","kind":"gift","acquired":false,"shares":132730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the \"Henshall Trust\").  The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the \"Henshall Trust\").  The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-029864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322029864/doc4.xml","form_type":"4"}},{"id":2172935,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-08-26T16:30:58.000Z","date":"2022-07-05","kind":"gift","acquired":true,"shares":48202,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust."}],"balance_after":132729,"source":{"system":"sec-edgar","filing":"0000899243-22-029864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322029864/doc4.xml","form_type":"4"}},{"id":2172934,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-08-26T16:30:58.000Z","date":"2022-07-05","kind":"gift","acquired":false,"shares":48202,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust."}],"balance_after":132730,"source":{"system":"sec-edgar","filing":"0000899243-22-029864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322029864/doc4.xml","form_type":"4"}},{"id":2172933,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-08-26T16:30:58.000Z","date":"2022-07-05","kind":"gift","acquired":true,"shares":84527,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the \"Menzel Trust\").  The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities.  The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the \"Menzel Trust\").  The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities.  The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the \"Menzel Trust\").  The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities.  The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust."}],"balance_after":84527,"source":{"system":"sec-edgar","filing":"0000899243-22-029864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322029864/doc4.xml","form_type":"4"}},{"id":2172932,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-08-26T16:30:58.000Z","date":"2022-07-05","kind":"gift","acquired":false,"shares":84527,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the \"Menzel Trust\").  The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities.  The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the \"Menzel Trust\").  The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities.  The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-029864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322029864/doc4.xml","form_type":"4"}},{"id":2234207,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T23:04:22.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":2.14,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-22-006516","document":"form4-06132022_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588922006516/form4-06132022_040607.xml","form_type":"4"}},{"id":2239119,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-08T21:00:49.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest on June 7, 2023 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":12.96,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-22-035079","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919122035079/doc4.xml","form_type":"4"}},{"id":2324786,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-18T16:24:13.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":1425,"price":2.3,"value":3277.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of September 1, 2021 through February 28, 2022. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2022."}],"balance_after":180932,"source":{"system":"sec-edgar","filing":"0001209191-22-020025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919122020025/doc4.xml","form_type":"4"}},{"id":2477334,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-10T16:32:50.000Z","date":"2021-12-09","kind":"grant","acquired":true,"shares":305800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter"}],"balance_after":305800,"derivative":{"exercise_price":5.21,"expiration_date":"2031-12-08","underlying":"Common Stock","underlying_shares":305800},"source":{"system":"sec-edgar","filing":"0001209191-21-069050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121069050/doc4.xml","form_type":"4"}},{"id":2477333,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-10T16:32:50.000Z","date":"2021-12-10","kind":"exercise","acquired":true,"shares":5946,"price":0.74,"value":4400.04,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of this option vested and became exercisable on December 6, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":138031,"derivative":{"exercise_price":0.74,"expiration_date":"2027-12-06","underlying":"Common Stock","underlying_shares":5946},"source":{"system":"sec-edgar","filing":"0001209191-21-069050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121069050/doc4.xml","form_type":"4"}},{"id":2477332,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-10T16:32:50.000Z","date":"2021-12-10","kind":"exercise","acquired":true,"shares":169054,"price":0.74,"value":125099.96,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted an option to purchase 253,581 shares on December 13, 2016. 84,527 of such options were previously exercised. 25% of this option vested and became exercisable on October 17, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":0.74,"expiration_date":"2026-12-12","underlying":"Common Stock","underlying_shares":169054},"source":{"system":"sec-edgar","filing":"0001209191-21-069050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121069050/doc4.xml","form_type":"4"}},{"id":2477331,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-10T16:32:50.000Z","date":"2021-12-09","kind":"exercise","acquired":true,"shares":175000,"price":0.74,"value":129500.0,"ownership":{"direct":true},"balance_after":179507,"source":{"system":"sec-edgar","filing":"0001209191-21-069050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121069050/doc4.xml","form_type":"4"}},{"id":2477330,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-10T16:32:50.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":422,"price":14.26,"value":6017.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021."}],"balance_after":4507,"source":{"system":"sec-edgar","filing":"0001209191-21-069050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121069050/doc4.xml","form_type":"4"}},{"id":2654764,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-06-25T21:01:02.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":11650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's  continued service on such  vesting date."}],"balance_after":11650,"derivative":{"exercise_price":40.37,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":11650},"source":{"system":"sec-edgar","filing":"0001209191-21-043335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919121043335/doc4.xml","form_type":"4"}},{"id":2658875,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T22:15:43.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":15000,"derivative":{"exercise_price":12.55,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-21-084245","document":"tm2120371-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921084245/tm2120371-5_4seq1.xml","form_type":"4"}},{"id":2740935,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-24T01:14:47.000Z","date":"2021-04-20","kind":"grant","acquired":true,"shares":14921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2021 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":14921,"derivative":{"exercise_price":24.33,"expiration_date":"2031-04-19","underlying":"Common Stock","underlying_shares":14921},"source":{"system":"sec-edgar","filing":"0001104659-21-054611","document":"tm2113912-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921054611/tm2113912-2_4seq1.xml","form_type":"4"}},{"id":2803394,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-08T08:16:12.000Z","date":"2021-02-28","kind":"grant","acquired":true,"shares":686,"price":16.1245,"value":11061.407,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 1, 2020 through February 28, 2021. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on September 1, 2020."}],"balance_after":4085,"source":{"system":"sec-edgar","filing":"0000899243-21-010266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924321010266/doc4.xml","form_type":"4"}},{"id":2803393,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-08T08:16:12.000Z","date":"2020-08-31","kind":"grant","acquired":true,"shares":1132,"price":10.098,"value":11430.936,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of March 1, 2020 through August 31, 2020.  This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020."}],"balance_after":3399,"source":{"system":"sec-edgar","filing":"0000899243-21-010266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924321010266/doc4.xml","form_type":"4"}},{"id":2893481,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-01-27T22:19:16.000Z","date":"2020-08-13","kind":"grant","acquired":true,"shares":29555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 1/12th of the total shares on November 13, 2020, and then 1/12th of the total shares vest quarterly thereafter, subject to the  reporting person's continued service to the issuer through each vesting date."}],"balance_after":29555,"derivative":{"exercise_price":28.57,"expiration_date":"2030-08-13","underlying":"Common Stock","underlying_shares":29555},"source":{"system":"sec-edgar","filing":"0001209191-21-005724","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000120919121005724/doc4.xml","form_type":"4"}},{"id":2948778,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-11T06:17:20.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":245000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":245000,"derivative":{"exercise_price":31.38,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":245000},"source":{"system":"sec-edgar","filing":"0000899243-20-033476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924320033476/doc4.xml","form_type":"4"}},{"id":3193308,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-27T16:15:26.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":1287,"price":10.1,"value":12998.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 2, 2019 through February 28, 2020. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020."}],"balance_after":2267,"source":{"system":"sec-edgar","filing":"0001209191-20-021382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919120021382/doc4.xml","form_type":"4"}},{"id":3193307,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-27T16:15:26.000Z","date":"2019-08-30","kind":"grant","acquired":true,"shares":980,"price":12.75,"value":12495.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of February 13, 2019 through August 30, 2019.  This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2019."}],"balance_after":980,"source":{"system":"sec-edgar","filing":"0001209191-20-021382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919120021382/doc4.xml","form_type":"4"}},{"id":3288849,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-02-05T22:56:46.000Z","date":"2020-02-03","kind":"exercise","acquired":false,"shares":156297,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":51825},"source":{"system":"sec-edgar","filing":"0000899243-20-003357","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320003357/doc4.xml","form_type":"4"}},{"id":3288848,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-05T22:56:46.000Z","date":"2020-02-03","kind":"exercise","acquired":true,"shares":51825,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities."}],"balance_after":51825,"source":{"system":"sec-edgar","filing":"0000899243-20-003357","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320003357/doc4.xml","form_type":"4"}},{"id":3334040,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-20T19:45:01.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":168000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 1, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":168000,"derivative":{"exercise_price":16.1,"expiration_date":"2029-12-18","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0000899243-19-029860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319029860/doc4.xml","form_type":"4"}},{"id":3556741,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-12T16:07:35.000Z","date":"2019-04-11","kind":"grant","acquired":true,"shares":486106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":486106,"derivative":{"exercise_price":16.11,"expiration_date":"2029-04-10","underlying":"Common Stock","underlying_shares":486106},"source":{"system":"sec-edgar","filing":"0001750019-19-000023","document":"wf-form4_155509964116859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000175001919000023/wf-form4_155509964116859.xml","form_type":"4"}}]}